Table 1. The clinico-pathologic characteristics of patients at time of initial diagnosis (n = 235).
| Parameters | Value | |
|---|---|---|
| Median age (range) (years) | 47 (27–83) | |
| Interval to recurrence from mastectomy (mos) | 33.2 (4.5–236) | |
| Menopausal status | Pre- Post- |
139 (59.1%) 96 (40.9%) |
| Location of primary tumor | Medial Central Outer |
88 (37.4%) 12 (5.1%) 135 (57.3%) |
| Primary tumor histopathology | IDC Others |
222 (94.5%) 13 (5.5%) |
| Primary tumor stage | pT1 pT2 pT3 Unknown |
76 (32.3%) 139 (59.1%) 15 (6.4%) 5 (2.1%) |
| Tumor grade | 1 2 3 |
17 (7.2%) 114 (48.5%) 104 (44.3%) |
| No. of nodes removed | 12 (6–30) | |
| Nodal stages | pN0 pN1 pN2 pN3 |
129 (54.9%) 79 (33.6%) 19 (8.1%) 8 (3.4%) |
| ER status | Positive Negative |
149 (63.4%) 86 (36.6%) |
| PR status | Positive Negative |
130 (55.3%) 105 (44.7%) |
| HER2 status | 0~+ ++ +++ |
167 (71.1%) 32 (13.6%) 36 (15.3%) |
| Biologic subtype | Luminal A Luminal B Luminal HER2 HER2 Triple negative |
83 (35.3%) 58 (24.7%) 23 (9.8%) 22 (9.4%) 49 (20.9%) |
| Primary surgery | MRM Others |
204 (86.8%) 31 (13.2%) |
| Initial systemic therapy | Chemotherapy only Endocrine therapy only Chemotherapy + endocrine therapy Trastuzumab None |
88 (37.4%) 11 (4.7%) 130 (55.3%) 3 (1.3%) 6 (2.6%) |
Abbreviations: ILRR = isolated locoregional recurrence; IDC = invasive ductal carcinoma; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; MRM = modified radical mastectomy